Shanghai Henlius Biotech Past Earnings Performance
Past criteria checks 3/6
Shanghai Henlius Biotech has been growing earnings at an average annual rate of 17.8%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 64.1% per year. Shanghai Henlius Biotech's return on equity is 24.9%, and it has net margins of 10.1%.
Key information
17.8%
Earnings growth rate
20.1%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 64.1% |
| Return on equity | 24.9% |
| Net Margin | 10.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 25
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking
Mar 10Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load
Dec 31The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business
Nov 25Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
Sep 18Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet
Aug 03Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?
May 31Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues
Apr 06Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
Sep 22Revenue & Expenses BreakdownBeta
How Shanghai Henlius Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,395 | 546 | 2,168 | 1,119 |
| 30 Sep 23 | 5,008 | 55 | 1,914 | 1,309 |
| 30 Jun 23 | 4,426 | -203 | 1,812 | 1,408 |
| 31 Mar 23 | 3,820 | -449 | 1,609 | 1,401 |
| 31 Dec 22 | 3,215 | -695 | 1,604 | 1,395 |
| 30 Sep 22 | 2,659 | -638 | 1,248 | 1,189 |
| 30 Jun 22 | 2,338 | -842 | 1,025 | 1,107 |
| 31 Mar 22 | 2,010 | -913 | 913 | 1,065 |
| 31 Dec 21 | 1,682 | -984 | 801 | 1,024 |
| 30 Sep 21 | 1,397 | -962 | 716 | 988 |
| 30 Jun 21 | 1,111 | -939 | 632 | 953 |
| 31 Mar 21 | 849 | -966 | 534 | 924 |
| 31 Dec 20 | 588 | -994 | 436 | 894 |
| 30 Sep 20 | 386 | -1,000 | 349 | 835 |
| 30 Jun 20 | 184 | -1,007 | 262 | 776 |
| 31 Mar 20 | 145 | -941 | 243 | 704 |
| 31 Dec 19 | 91 | -875 | 221 | 608 |
| 30 Sep 19 | 58 | -747 | 185 | 525 |
| 30 Jun 19 | 24 | -619 | 150 | 441 |
| 31 Mar 19 | 8 | -591 | 131 | 416 |
| 31 Dec 18 | 7 | -494 | 109 | 365 |
| 31 Dec 17 | 34 | -271 | 87 | 257 |
Quality Earnings: 2696 has high quality earnings.
Growing Profit Margin: 2696 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2696 has become profitable over the past 5 years, growing earnings by 17.8% per year.
Accelerating Growth: 2696 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 2696 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: Whilst 2696's Return on Equity (24.91%) is high, this metric is skewed due to their high level of debt.